I'm LongbridgeAI, I can summarize articles.AbbVie (ABBV) ended the week up 0.14% at $264.34, underperforming the S&P 500, which gained 1.21%. Trading was choppy: the stock opened Monday at $263.07, hit a weekly high of $269.39 on Wednesday, then pulled back and settled near $264.34 by Friday. The week’s range was about 3.1%. Volume was thin, with the daily average roughly a third below the median.
The Week
AbbVie (ABBV) ended the week up 0.14% at $264.34, underperforming the S&P 500, which gained 1.21%. Trading was choppy: the stock opened Monday at $263.07, hit a weekly high of $269.39 on Wednesday, then pulled back and settled near $264.34 by Friday. The week’s range was about 3.1%. Volume was thin, with the daily average roughly a third below the median.
Key Events
The week’s news centred on product approvals and AI partnerships. On Monday, AbbVie announced a collaboration with Iambic to speed up AI-driven drug discovery, and on Thursday it expanded its AI push through new partnerships and an industry initiative. On the regulatory side, the European Commission approved RINVOQ for children with active polyarticular juvenile idiopathic arthritis on Tuesday, and Health Canada approved the EPKINLY combination for relapsed or refractory follicular lymphoma in adults on Thursday. After the trading week closed, the US FDA approved AbbVie’s drug for Parkinson’s disease, setting up a potential catalyst for the coming week.
Analyst Ratings
As of 25 September, 30 brokers cover the stock: 8 rate it strong buy, 16 rate it buy, 5 hold, and 1 underperform, with no sell ratings. The consensus rating is buy, with a consensus target of $278.61, about 5.4% above the current price. Targets range widely from $200 to $328. In the biotech sector, AbbVie ranks 4th out of 506 companies.
The Week Ahead
Next week’s macro calendar brings several housing and jobs readings, including FHFA house prices, the Case Shiller 20-city index, JOLTS job openings, and consumer confidence on 29 September. For AbbVie, the market’s reaction to the FDA’s Parkinson’s drug approval and any follow-through on the AI partnerships will be the more direct focus.
In Short
AbbVie held steady this week, with product approvals and AI partnerships providing event-driven support and broker ratings staying positive, with the consensus target above spot. But turnover was light and the stock lagged the benchmark, suggesting the good news has not yet translated into meaningful buying. The key question now is whether the FDA approval for the Parkinson’s drug sparks a stronger response and whether the AI push leads to tangible pipeline updates.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.